NASDAQ:CYTK - Cytokinetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.70 -0.21 (-2.65 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$7.70
Today's Range$7.68 - $8.10
52-Week Range$6.02 - $10.26
Volume323,048 shs
Average Volume244,944 shs
Market Capitalization$432.76 million
P/E Ratio-2.97
Dividend YieldN/A
Beta2.01
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
Previous Symbol
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.73
Current Ratio10.57
Quick Ratio10.58

Price-To-Earnings

Trailing P/E Ratio-2.97
Forward P/E Ratio-3.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million
Price / Sales31.51
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.04 per share
Price / Book3.77

Profitability

EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net MarginsN/A
Return on Equity-142.94%
Return on Assets-45.73%

Miscellaneous

Employees137
Outstanding Shares54,710,000
Market Cap$432.76 million
OptionableOptionable

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.11. The biopharmaceutical company had revenue of $10.64 million for the quarter, compared to analysts' expectations of $2.23 million. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

5 analysts have issued twelve-month price objectives for Cytokinetics' stock. Their predictions range from $10.00 to $21.00. On average, they anticipate Cytokinetics' stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 79.2% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. Cantor Fitzgerald analysts commented, "We have an Overweight rating based on ome’ in chronic HF and relde’ in SMA & ALS. For ome’, GALACTIC-HF data are expected in 2021, with interim reads in ’19 (futility) and ’20 (efficacy) that may lead to milestone payments to CYTK. Recent relde’ P2 data in SMA showed clinical benefit in 6MWD & MEP which enhances PoS in Type III SMA in our view. With VITALITY-ALS lessons learned & SMA PoC in hand, we are cautiously optimistic on relde’ prospects and believe investors may be overlooking potential value creation within the next 12 months." (12/5/2018)
  • 2. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We maintain our Buy rating and $21 price target. We highlight that omecamtiv, partnered globally with Amgen, drives the lion’s share of our current valuation (>80%). Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch." (11/27/2018)
  • 3. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (11/2/2018)

Has Cytokinetics been receiving favorable news coverage?

Headlines about CYTK stock have been trending somewhat positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cytokinetics earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future.

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.92%), Vanguard Group Inc. (6.29%), Vanguard Group Inc (6.29%), FMR LLC (3.58%), Wasatch Advisors Inc. (3.46%) and Pinnacle Associates Ltd. (1.19%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Morgan Stanley, Virtus ETF Advisers LLC and Credit Suisse AG. Company insiders that have sold Cytokinetics company stock in the last year include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Marshall Wace North America L.P., FMR LLC, Wasatch Advisors Inc., Bank of New York Mellon Corp, Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $7.70.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $432.76 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  542 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel